Novo Nordisk Strikes $2.1B Vivtex Deal While Stock Sinks 40%
Novo Nordisk licensed Vivtex’s oral obesity drug technology in a deal valued at up to $2.1 billion, broadening its GLP-1 obesity treatment pipeline. The stock has fallen over 40% this month to trade at 10.6x trailing earnings, underscoring a deep-value setup after growth expectations reset.
1. Vivtex Licensing Deal Details
Novo Nordisk entered a licensing agreement with Vivtex for oral obesity drug delivery technology in a deal valued at up to $2.1 billion, reflecting the company’s effort to enhance its GLP-1 obesity portfolio with novel formulation capabilities.
2. Stock Decline and Valuation Reset
Shares have plunged more than 40% this month, erasing prior gains and driving the stock to trade at approximately 10.6 times trailing earnings, a significant discount to obesity-drug rival multiples.
3. Deep-Value Opportunity Analysis
The sharp valuation reset, with an earnings yield near 9.4%, reflects concerns over competition and pricing pressure but may present a deep-value entry point given Novo Nordisk’s leading position in the global obesity drug market.